Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 990

1.

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C.

Gastroenterology. 2003 Mar;124(3):642-50.

PMID:
12612903
2.

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2002 Nov;8(11):1000-6.

3.

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J.

N Engl J Med. 1998 Nov 19;339(21):1493-9.

4.

[Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].

Lengyel G, Kóbori L, Fehérvári I, Nemes B, Görög D, Patonai A, Sárváry E, Varga M, Perner F, Fehér J.

Orv Hetil. 2003 Nov 30;144(48):2367-70. Hungarian.

PMID:
14753031
5.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group.

J Hepatol. 2002 May;36(5):672-80.

PMID:
11983451
7.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
8.

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.

Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, Piscaglia F, Andreone P; Bologna Liver Transplantation Group (BLTG), Ballardini G, Bernardi M, Bianchi FB, Biselli M, Bolondi L, Cescon M, Colecchia A, D'Errico A, Del Gaudio M, Ercolani G, Grazi GL, Grigioni W, Lorenzini S, Pinna AD, Ravaioli M, Roda E, Sama C, Vivarelli M.

Aliment Pharmacol Ther. 2008 Aug 15;28(4):450-7. doi: 10.1111/j.1365-2036.2008.03761.x. Epub 2008 Jun 11.

9.

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK.

N Engl J Med. 1998 Nov 19;339(21):1485-92.

10.

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.

Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, Cariti G, Andreoni M, Biglino A, Calleri G, Maggi G, Tappero GF, Orsi PG, Terreni N, Macor A, Di Napoli A, Rinaldi E, Ciccone G, Rizzetto M.

Hepatology. 2001 Jul;34(1):133-8.

PMID:
11431744
11.

First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.

Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1299-304.

PMID:
14624153
12.

Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.

el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S.

Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):472-5.

PMID:
10575565
13.
14.

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

Enríquez J, Gallego A, Torras X, Pérez-Olmeda T, Diago M, Soriano V, Luján MS, García-Samaniego J.

J Viral Hepat. 2000 Nov;7(6):403-8.

PMID:
11115050
15.

Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.

Yedibela S, Schuppan D, Müller V, Schellerer V, Tannapfel A, Hohenberger W, Meyer T.

Liver Int. 2005 Aug;25(4):717-22.

PMID:
15998420
16.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo).

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
17.

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.

Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.

J Hepatol. 2005 Jul;43(1):53-9. Epub 2005 Apr 11.

PMID:
15876467
18.
19.
20.

Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.

Younossi ZM, Mullen KD, Hodnick S, Barnes DS, Carey WD, McCullough AC, Easley K, Gramlich T, Liebermann BY.

J Clin Gastroenterol. 2003 May-Jun;36(5):427-30.

PMID:
12702987
Items per page

Supplemental Content

Write to the Help Desk